[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645521":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":25,"locations":31,"responsibleParty":47,"collaborators":24,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":24,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":24,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":34,"whyStopped":24,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Ruijin Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"directional PSA-STN","EXPERIMENTAL","Participants randomized in this arm will receive the bilateral directional PSA stimulation and then will be crossovered to the bilateral directional STN stimulation in the acute mapping phase (phase I). After that, participants will receive the bilateral directional PSA stimulation in the first two months in the chronic randomized phase (phase II) and then will be crossovered to the bilateral directional STN stimulation for another two months.",[13],"Device: directional Deep brain stimulation",{"label":15,"type":10,"description":16,"interventionNames":17},"directional STN-PSA","Participants randomized in this arm will receive the bilateral directional STN stimulation and then will be crossovered to the bilateral directional PSA stimulation in the acute mapping phase (phase I). After that, participants will receive the bilateral directional STN stimulation in the first two months in the chronic randomized phase (phase II) and then will be crossovered to the bilateral directional PSA stimulation for another two months.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DEVICE","directional Deep brain stimulation","active directional DBS with optimal stimulating parameters",[9,15],null,[26],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},"Dianyou Li, MD, PhD","CONTACT","+0086-021-64370045","ldy11483@rjh.com.cn",[32],{"facility":33,"status":34,"city":35,"state":24,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine","RECRUITING","Shanghai","200025","China","CN",{"type":40,"coordinates":41},"Point",[42,43],121.45806,31.22222,{"lat":43,"lon":42},[46],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},{"type":48,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","LI DIANYOU","MD, PhD","100645521","directional-psa-versus-stn-dbs-for-td-pd-100645521",false,"NCT07700862","Directional PSA Versus STN DBS for TD-PD","Directional Deep Brain Stimulation of the Posterior Subthalamic Area (PSA) Versus Subthalamic Nucleus (STN) for Tremor-dominant Parkinson's Disease: a Prospective, Randomized, Double-blinded, Cross-over Trial","Inclusion Criteria:\n\n* diagnosis of idiopathic Parkinson's disease\n* tremor-dominant subtype in the off-medication condition\n* modified Hoehn-Yahr scale of 2 to 4 in the off-medication condition\n* receiving regular anti-parkinsonian drugs for more than 6 weeks\n* good compliance and written informed consent provided\n\nExclusion Criteria:\n\n* Atypical parkinsonism\n* History of stroke, encephalitis, neuroleptic uses, MRI scan with evidence of significant brain atrophy, lacunar infracts, or other conditions that might interfere with the intracranial surgery\n* Presence of cognitive, or psychiatric or other co-morbidities (e.g., dementia, epilepsy, cranial traumatism, brain tumor, schizophrenia, severe depression or bipolar disorder, personality disorder, etc.) that might interfere with the patient's ability to complete the evaluations or to provide informed consent\n* Presence of anatomical abnormalities in the target region\n* Clinically significant medical history that would increase pre-\u002Fpost-operative complications\n* Other conditions considered by the investigators that might interfere with the surgery procedure, the follow-ups, and the interpretation of the data","ALL","18 Years","80 Years",{"count":62,"type":63},32,"ESTIMATED","INTERVENTIONAL",[66],"NA","The aim of this study is to compare the effectiveness of the deep brain stimulation in the posterior subthalamic area (PSA) versus the subthalamic nucleus (STN) using directional lead for the treatment of tremor-dominant Parkinson's disease (PD) in a randomized, double-blinded, cross-over manner.",[69],"Parkinsons Disease (PD)",[71,72,73,74],"tremor-dominant Parkinson's disease","directional deep brain stimulation","posterior subthalamic area","subthalamic nucleus","2026-07-07",{"date":77,"type":78},"2026-07-14","ACTUAL",{"date":80,"type":78},"2026-07-01",{"date":82,"type":63},"2029-06",{"name":5,"class":6},1]